BJBowen Jin

Bowen Jin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bowen Jin has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Microglia from individuals with mild cognitive impairment (MCI) and AD show differences in transcriptional burst kinetics

    by Bowen Jin, Margaret A. Pericak‐Vance, Eden R. Martin, Lindsay A. Farrer, Jonathan L. Haines, William S. Bush

    Background: Microglia are the innate immune cells in the central nervous system that responds to brain injury and pathogens. The loss of homeostatic microglia is associated with neurodegenerative diseases. Multiple studies of AD mouse models have identified AD‐associated microglia subtypes, e.g., disease associated microglia (DAM). However, studies of human microglia have not reported similar microglia subtypes. Therefore, how human microglia change in the presence of amyloid‐ protein deposition and phosphorylated Tau remains an open question.Method: We have developed an approach that estimates transcriptional kinetics from scRNA‐seq data. This approach models how “bursty” and variable a gene expression is. We hypothesize that transcriptional bursts of key genes are different within AD cases compared to MCI individuals. We used the ROSMAP scRNAseq microglia dataset of 8 AD cases and 4 MCI cases and applied our approach to estimate the transcriptional kinetics for each subject. We then compared the difference in transcriptional kinetics of genes that are estimated both in AD and MCI.Result: First, we found that 96% of microglia cells in AD and MCI shows a similar co‐occurrence pattern of expressed genes and, therefore, likely reflect the same cell type. Within the assumed homogeneous microglia cells, we identified two genes, C1QC and ACTB, showing significant differences in their transcriptional kinetics between AD and MCI cases. Both C1QC and ACTB show larger burst sizes in MCI than in AD cases (p‐value for C1QC:0.0038; p‐value for ACTB: 0.00918). Consequently, C1QC and ACTB show a higher expression level variability among microglia cells in MCI cases than AD.Conclusion: Our result suggests C1QC and ACTB may be associated with AD risk via changes in variability of gene expression rather than total gene expression levels. The increased variability in transcription of C1QC and ACTB in MCI individuals relative to AD cases might indicate more mobile and active physiological states of microglia. These results may point to functional changes in these genes with AD progression and are prime targets for further experimental validation.

  • Open Access

    Spatial Distribution of Missense Variants within Complement Proteins Associates with Age Related Macular Degeneration

    by Michelle Grunin, Sarah de Jong, Ellen L Palmer, Bowen Jin, David Rinker, Christopher Moth, Anthony Capra, Jonathan L. Haines, William S Bush, Anneke I. Den Hollander, et al.

    Purpose: Genetic variants in complement genes are associated with age-related macular degeneration (AMD). However, many rare variants have been identified in these genes, but have an unknown significance, and their impact on protein function and structure is still unknown. We set out to address this issue by evaluating the spatial placement and impact on protein structureof these variants by developing an analytical pipeline and applying it to the International AMD Genomics Consortium (IAMDGC) dataset (16,144 AMD cases, 17,832 controls). Methods: The IAMDGC dataset was imputed using the Haplotype Reference Consortium (HRC), leading to an improvement of over 30% more imputed variants, over the original 1000 Genomes imputation. Variants were extracted for the CFH , CFI , CFB , C9 , and C3 genes, and filtered for missense variants in solved protein structures. We evaluated these variants as to their placement in the three-dimensional structure of the protein (i.e. spatial proximity in the protein), as well as AMD association. We applied several pipelines to a) calculate spatial proximity to known AMD variants versus gnomAD variants, b) assess a variant’s likelihood of causing protein destabilization via calculation of predicted free energy change (ddG) using Rosetta, and c) whole gene-based testing to test for statistical associations. Gene-based testing using seqMeta was performed using a) all variants b) variants near known AMD variants or c) with a ddG >|2|. Further, we applied a structural kernel adaptation of SKAT testing (POKEMON) to confirm the association of spatial distributions of missense variants to AMD. Finally, we used logistic regression on known AMD variants in CFI to identify variants leading to >50% reduction in protein expression from known AMD patient carriers of CFI variants compared to wild type (as determined by in vitro experiments) to determine the pipeline’s robustness in identifying AMD-relevant variants. These results were compared to functional impact scores, ie CADD values > 10, which indicate if a variant may have a large functional impact genomewide, to determine if our metrics have better discriminative power than existing variant assessment methods. Once our pipeline had been validated, we then performed a priori selection of variants using this pipeline methodology, and tested AMD patient cell lines that carried those selected variants from the EUGENDA cohort (n=34). We investigated complement pathway protein expression in vitro , looking at multiple components of the complement factor pathway in patient carriers of bioinformatically identified variants. Results: Multiple variants were found with a ddG>|2| in each complement gene investigated. Gene-based tests using known and novel missense variants identified significant associations of the C3 , C9 , CFB , and CFH genes with AMD risk after controlling for age and sex (P=3.22×10 −5 ;7.58×10 −6 ;2.1×10 −3 ;1.2×10 −31 ). ddG filtering and SKAT-O tests indicate that missense variants that are predicted to destabilize the protein, in both CFI and CFH, are associated with AMD (P=CFH:0.05, CFI:0.01, threshold of 0.05 significance). Our structural kernel approach identified spatial associations for AMD risk within the protein structures for C3, C9, CFB, CFH, and CFI at a nominal p-value of 0.05. Both ddG and CADD scores were predictive of reduced CFI protein expression, with ROC curve analyses indicating ddG is a better predictor (AUCs of 0.76 and 0.69, respectively). A priori in vitro analysis of variants in all complement factor genes indicated that several variants identified via bioinformatics programs PathProx/POKEMON in our pipeline via in vitro experiments caused significant change in complement protein expression (P=0.04) in actual patient carriers of those variants, via ELISA testing of proteins in the complement factor pathway, and were previously unknown to contribute to AMD pathogenesis. Conclusion: We demonstrate for the first time that missense variants in complement genes cluster together spatially and are associated with AMD case/control status. Using this method, we can identify CFI and CFH variants of previously unknown significance that are predicted to destabilize the proteins. These variants, both in and outside spatial clusters, can predict in-vitro tested CFI protein expression changes, and we hypothesize the same is true for CFH . A priori identification of variants that impact gene expression allow for classification for previously classified as VUS. Further investigation is needed to validate the models for additional variants and to be applied to all AMD-associated genes.

  • Open Access

    Allelic Transcription Factor binding shape transcriptional kinetics observed with scRNA-seq in human cell lines

    by Bowen Jin, Hao Feng, William S. Bush

    Gene expression from bulk RNA-seq studies is an average measurement between two chromosomes and across cell populations. Both allelic and cell-to-cell heterogeneity in gene expression results from promoter bursting patterns that repeatedly alternate between an activated and inactivated state. Increased cell-to-cell heterogeneity in gene expression has been associated with aging and stem cell pluripotency. However, studies of bursting kinetics and their molecular mechanism are relatively limited in human cells compared to other species due to laborious single-molecule experiments. Here, we systematically investigate the regulatory effect of genetic variants and transcription factor (TF) binding on transcriptional kinetics at the single chromosome level with GM12878. We found that the transcription initiation rate and burst frequency correlate most with eQTL effect sizes among transcriptional kinetics, which suggests that eQTLs affect average gene expression mainly through altering burst kinetics. We further found that ∼90% of the variance of burst frequency can be explained by TF occupancy in phase with the core promoter. We identified and replicated several examples where eQTL or GWAS catalog loci perturb TF binding affinity and are consequently associated with the change of burst kinetics.

  • Open Access

    An association test of the spatial distribution of rare missense variants within protein structures identifies Alzheimer's disease–related patterns

    by Bowen Jin, John A. Capra, Penelope Benchek, Nicholas R Wheeler, Adam C. Naj, Kara L. Hamilton-Nelson, John J. Farrell, Yuk Yee Leung, Brian W Kunkle, Badri N Vardarajan, et al.

    More than 90% of genetic variants are rare in most modern sequencing studies, such as the Alzheimer's Disease Sequencing Project (ADSP) whole-exome sequencing (WES) data. Furthermore, 54% of the rare variants in ADSP WES are singletons. However, both single variant and unit-based tests are limited in their statistical power to detect an association between rare variants and phenotypes. To best use missense rare variants and investigate their biological effect, we examine their association with phenotypes in the context of protein structures. We developed a protein structure–based approach, protein optimized kernel evaluation of missense nucleotides (POKEMON), which evaluates rare missense variants based on their spatial distribution within a protein rather than their allele frequency. The hypothesis behind this test is that the three-dimensional spatial distribution of variants within a protein structure provides functional context to power an association test. POKEMON identified three candidate genes (TREM2, SORL1, and EXOC3L4) and another suggestive gene from the ADSP WES data. For TREM2 and SORL1, two known Alzheimer's disease (AD) genes, the signal from the spatial cluster is stable even if we exclude known AD risk variants, indicating the presence of additional low-frequency risk variants within these genes. EXOC3L4 is a novel AD risk gene that has a cluster of variants primarily shared by case subjects around the Sec6 domain. This cluster is also validated in an independent replication data set and a validation data set with a larger sample size.


  • [Efficacy and safety of percutaneous transluminal pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension].

    by B W Jin, G C Zhang, Q S Shen, K Long

    Objective: To explore the efficacy and safety of percutaneous transluminal pulmonary angioplasty (PTPA) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). Methods: This prospective single arm study included 19 CTEPH patients (7 male, age(56.3±12.5)years) admitted to Wuhan Asia Heart Hospital from January 2017 to June 2019 and received PTPA interventional therapy. Baseline data, including age, sex, WHO functional class, 6-minute walk distance (6MWD), NT-proBNP, right heart catheterization values, were collected. Patients received single or repeated PTPA. Number of dilated vessels from each patient was analyzed, patients were followed up for 24 weeks and right heart catheterization was repeated at 24 weeks post initial PTPA. All-cause death, perioperative complications, and reperfusion pulmonary edema were reported. WHO functional class, 6MWD, NT-proBNP, right heart catheterization values were compared between baseline and at 24 weeks follow up. Results: Nineteen CTEPH patients received a total of 56 PTPA treatments. The pulmonary artery pressure (mPAP) decreased from (40.11±7.55) mmHg (1 mmHg=0.133 kPa) to (27.53±4.75) mmHg (PPPPP=0.002), the NT-proBNP decreased at 24 weeks post PTPA (P=0.002). During the follow-up period, there was no death; hemoptysis occurred in 4 patients during the operation, none of which resulted in serious adverse clinical consequences. One patient developed reperfusion pulmonary edema and recovered after treatment. Conclusion: PTPA treatment is safe and can significantly improve the hemodynamics and WHO functional class of patients with CTEPH.

  • Open Access

    Understanding the current status of patients with pulmonary hypertension during COVID‐19 outbreak: a small‐scale national survey from China

    by Hongmei Zhou, Gangcheng Zhang, Xiaoxian Deng, Bowen Jin, Qiu Qiu, Menghuan Yan, Xi Wang, Xuan Zheng

    Pulmonary hypertension is a chronic disease developing progressively with high mortality. Pulmonary hypertension patients need persistent medical care; however, limited reports focused on them when there was an outbreak of coronavirus disease 2019 in China. This national survey was aimed to evaluate the overall condition of pulmonary hypertension patients during this period. A questionnaire regarding the living condition of pulmonary hypertension patients during coronavirus disease 2019 was designed by pulmonary hypertension diagnostic experts in Wuhan Asia Heart Hospital. Pulmonary hypertension patients and their family members were invited to participate in this survey online. One‐hundred twenty pulmonary hypertension patients and 23 family members participated in the survey; 64.8% (n = 87) participants came from Hubei, and others were from 15 other provinces; 98.6% (n = 141) participants were in home quarantine; 65.8% (n = 79) were pulmonary arterial hypertension associated with congenital heart disease; and 76.7% (n = 92) patients proclaimed their heart function was well maintained at class I or II. One (0.8%) patient was confirmed severe acute respiratory syndrome coronavirus 2 infection. Two (1.7%) patients were hospitalized due to heart function worsening. Nearly 70% (n = 100) participants implied shortage in medications during coronavirus disease 2019 outbreak. A total of 24.2% (n = 29) patients indicated that medications were discontinued due to the insufficient supply. Most of the participants stayed optimistic on either coronavirus disease 2019 outbreak or their pulmonary hypertension disease, and 61.7% (n = 74) patients would go to the hospital for follow‐up immediately after outbreak. These preliminary data show pulmonary hypertension patients are able to avoid severe disease when they are in home quarantine. Medication supplement is important for pulmonary hypertension patients when their heart function is well maintained. In addition, there might be increasing requirements of medical care for pulmonary hypertension patients after the outbreak.